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Introduction: The role of p16 is gaining importance in non-small
cell lung cancer (NSCLC) because of epigenetic therapy options.
Further insight into the significance of protein expression, gene
status and promoter methylation is needed and has the potential to
optimize existing treatment strategies.
Methods: This population-based study analyzes p16 in 383 surgi-
cally resected non-small cell lung carcinomas brought into a stan-
dardized tissue microarray platform. Immunohistochemistry and
fluorescence in situ hybridization were performed. For selected
cases, p16 promoter hypermethylation was assessed by a pyrose-
quencing assay. Extensive clinical data and a postoperative fol-
low-up period of 15 years enabled detailed correlations.
Results: Loss of p16 expression is a common event in NSCLC
(232/365, 64%), especially in squamous cell carcinomas (97/115,
84%) in contrast to adenocarcinomas (93/186, 50%). Loss of p16
expression was associated with poorer survival time for the entire
cohort and for certain subgroups including men, age younger than 65
years, smokers, early tumor stage, adenocarcinoma, and large-cell
carcinoma. Promoter hypermethylation was absent for cases ex-
pressing p16 but was commonly observed when (heterozygous) p16
gene deletions were present and in cases negative for p16.
Conclusion: Our comprehensive data would be compatible with a
two-step process leading to loss of p16 expression in NSCLC.
Hypermethylation of the promoter region may represent an early
event, followed by heterozygous deletion of the p16 locus. Because of
the possibility of detection of hypermethylated gene regions, these data
may lead to the identification of specific patient subgroups more likely
to benefit from upcoming demethylating treatment strategies.
Key Words: p16, Expression, Deletion, Hypermethylation, Non-
small cell lung cancer.
(J Thorac Oncol. 2011;6: 1649–1657)
The p16 gene, a well-known tumor suppressor gene, islocalized on chromosome 9p21 and its product inhibits
cyclin D-dependent phosphorylation of the retinoblastoma
protein by binding the cyclin-dependent kinases (cdks), cdk4
and cdk6. Loss of p16 leads to phosphorylation of the
retinoblastoma protein, releasing cell cycle inhibition and
allowing uncontrolled progress from the G1- to the S-phase.
Loss of p16 has been described for a variety of tumors
including non-small cell lung cancer (NSCLC) and is usually
associated with worse prognosis.1 Major mechanisms of de-
creased activity of p16 include gene deletion and hypermeth-
ylation of the cytosine-phosphate diester-guanine island pro-
moter region, both being observed in NSCLC.2,3 DNA
methylation plays an essential role in the maintenance of
genomic stability; however, alterations in methylation pat-
terns frequently occur in tumor cells.4 Hypermethylation in
the promoter regions of tumor suppressor genes is commonly
associated with epigenetically mediated gene silencing.5 In
lung cancer, p16 gene hypermethylation has been detected in
17 to 84% of cases in a smoking habit-dependent manner and
may be a candidate marker for predicting the prognosis of
NSCLC.6,7 Gene promoter hypermethylation in sputum cells
has even been reported as a molecular marker for identifying
healthy individuals at high risk for cancer incidence.8 Epige-
netic changes involved in cancer development, unlike genetic
changes, are reversible. Thus, patients with NSCLC with
epigenetic alterations could benefit from treatment with dem-
ethylating agents after surgery. Azacytidine is the first DNA
hypomethylating agent approved by the Food and Drug
Administration for the treatment of myelodysplastic syn-
dromes with demonstrated efficacy, and prospective studies
in NSCLC with promising results are ongoing.9,10 So far,
predictive markers for response to demethylating agents have
not been established.
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To date, various detailed reports on p16 in NSCLC are
mainly concentrated on protein expression analysis by immu-
nohistochemistry.11–15 Studies concerning gene status and
hypermethylation of the promoter region are usually limited
to general findings without correlation with protein expres-
sion.2,6,7 We aimed to analyze a large group of surgically
resected NSCLC regarding p16 protein expression, p16 gene
copy number status, and for selected cases p16 gene promoter
hypermethylation. The relationship between protein expres-
sion, gene status, and promoter hypermethylation was exam-
ined and correlated with extensive clinical data over a fol-
low-up period of up to 15 years after surgical tumor resection.
MATERIALS AND METHODS
Patients and Tissue Sampling
The archival samples were derived from 383 patients
with NSCLC with radical surgical resection in curative intent
between 1992 and 2004 and diagnosed at the Institute for
Pathology, Medical University of Innsbruck. Cases were
selected only based on tissue preservation. Hematoxylin and
eosin (HE)-stained slides from all available specimens were
reclassified by two pathologists (W.S. and A.T.) without
knowledge of patient’s data, according to the current World
Health Organization classification of tumors of the lung as
described previously.16–18 Categories included squamous cell
carcinoma (SCC), adenocarcinoma (ACA), large-cell carci-
noma (LCC), adenosquamous carcinoma, sarcomatoid carci-
noma (which were all of the pleomorphic type), and mucoepi-
dermoid carcinoma. Carcinoids were excluded from this
analysis. Tumor differentiation was graded as well, moderate,
or poor. The clinical information was documented within the
Twelve Years Retrospective of Lung Cancer survey, a project
aiming to analyze various features of a large number of
patients with lung cancer.19 These patients mainly originated
from the Austrian province of Tyrol and were all treated at
the Medical University Hospital of Innsbruck and in associ-
ated hospitals. Approval for data acquisition and analysis was
obtained from the local Institutional Review Board, i.e., the
Ethics Committee of the Medical University of Innsbruck.
The basic patients’ characteristics including symptoms at
presentation, smoking habits, comorbidities, and laboratory
parameters, as well as the complete course of treatment
modalities, including surgery and all lines of chemotherapy
and radiotherapy and continuous follow-up and end point
data, were documented.19 Regarding therapy modalities, the
patients were routinely discussed at the Medical University of
Innsbruck Tumor Board, and a state of the art recommenda-
tion of therapy, adapted to the condition of the patient, was
given. Accordingly, there was a continuous shift of therapy
modalities routinely applied in this comparably large interval
of study recruitment.19,20
Tissue Microarray Construction
Tumor material consisted of paraffin-embedded tissue
after fixation in 10% neutral buffered formalin. The tissue
microarray (TMA) was constructed as previously de-
scribed.17,21 Briefly, representative intratumoral areas were
marked on HE-stained slides, and four cylindrical 0.6-mm
tissue cores each were arrayed from the corresponding par-
affin blocks into a recipient block using an arraying machine
from Beecher Instruments (Sun Prairie, WI). The core coor-
dinates were recorded for exact location using Microsoft
Excel (Microsoft, Redmond, WA) and printouts assisted the
subsequent immunohistochemical evaluation. Four-microm-
eter-thick paraffin sections were cut. The first section was
stained by HE to confirm validity, the rest were used for
immunohistochemistry. Adhesive transfer tape was not used.
Immunohistochemistry
For detection of p16, the ready to use kit of CINtec
(Heidelberg, Germany) was used. Immunohistochemistry
was performed using the automated staining system, Bench-
mark XT (Roche/Ventana Medical Systems, Tucson, AZ).
Antigen retrieval was done by CC1 buffer. Incubation lasted
for 32 minutes at 37°C. Diaminobenzidine was used as a
chromogen. Stainings for other markers were performed as
previously described.17,21 The percentage of positively
stained tumor cells was established by actual cell count
independently by two pathologists (W.S. and A.T.) to study
interobserver agreement. The percentage of positive tumor
cells was noted for each spot, followed by the calculation of
the arithmetic mean value. The prognostic relevance and the
cutoff score to determine positivity were assessed by means
of receiver operating characteristic (ROC) analysis, selecting
death as the state variable (see Statistical Analysis).22
Fluorescence In Situ Hybridization
To study the p16 gene status, interphase fluorescence in
situ hybridization (FISH) with a locus-specific identifier p16
(9p21) SpectrumOrange/chromosome enumeration probe
(CEP) 9 SpecturmGreen dual-color mix (05J51-001 from
Abbott/Vysis, Baar, Switzerland) was performed on TMA
sections according to the manufacturer’s protocol. The sec-
tions were further processed with a paraffin pretreatment
reagent kit (Abbott/Vysis), and hybridization was performed
as described in Vysis’ protocol. Denaturation lasted for 10
minutes at 73°C, and FISH mix was incubated overnight at
37°C in Hybrite (Abbott/Vysis). Slides were counterstained
with 125 ng/ml 4, 6-diamino-2-phenylindole in antifade
solution. FISH signals were visualized on a Zeiss fluores-
cence microscope equipped with double-band pass filters for
simultaneous visualization of green and red signals. Cases
were considered evaluable for FISH if at least 100 tumor cell
nuclei/core displayed positive signals. Red and green signals
were counted separately in 20 cells. The red to green ratio
was calculated mathematically. Deletions of 9p21 were de-
fined as red to green ratio below the mean minus 3 SDs of red
to green ratios in reference cases (normal lung parenchyma,
n  5), i.e., a ratio of less than 0.636. This cutoff score also
best discriminated between immunohistochemically p16-pos-
itive and -negative cases with a specificity of 60% and a
sensitivity of 45% as determined by ROC (see below), with
an area under the ROC of 0.601 (95% CI: 0.545–0.675, p 
0.001).
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p16 Pyrosequencing for the Detection of p16
Promoter Hypermethylation
Genomic DNA was extracted from paraffin-embedded
tumor tissue using the QIAamp DNA Mini Kit (Cat. No
51304, Qiagen, Valencia, CA). Universal Methylated Human
DNA Standard (Cat. No. D5011, Zymo Research Corp.,
Irvine, CA) was used as DNA methylation-positive control
and DNA from normal human lymphocytes as methylation-
negative control. Bisulfite conversion of the DNA was per-
formed using the EZ DNA Methylation-Gold Kit (Cat. No.
D5006, Zymo Research Corp.) according to the manufactur-
er’s instructions.
Polymerase chain reaction (PCR) amplification of
bisulfite-converted DNA was performed using specific p16
PCR primers resulting in a PCR product including five CpG
sites. For the first and the nested PCR, 40 amplification cycles
were performed. Two microliters of DNA was added in a
volume of 25 l containing dNTPs (0.2 mM final), PCR
Gold Buffer (1 final; Applied Biosystem), PCR primers
(0.12 M), and 0.2 l of Taq polymerase (ampliTaq Gold;
Applied Biosystem). The nested PCR was performed under
the same condition by adding 1 l of the amplicon in 25 l
of master mix.
Fifteen microliters of the biotinylated PCR product
were immobilized on streptavidin-coated sepharose beads by
mixing at 1400 rpm at a room temperature for 5 minutes.
Then beads with immobilized PCR product were picked up
by Vacuum Prep Tool from the PCR plate and moved to a
separate one. In this study, 70% ethanol is aspirated through
the filter probes and placed in a trough of sodium hydroxide
to denature the DNA (biot. DNA strand remains immobilized
on the beads). The tool is placed in a trough of washing buffer
and rinsed by aspiration. The single-stranded templates are
transferred to a prepared plate containing annealing buffer
and sequencing primer (25 l). Release of the beads takes
place with the template into the plate by switching off the
vacuum pressure. After that the annealing of primer can be
started at 80°C for 2 minutes, and the samples are ready for
analysis.
Pyrosequencing was subsequently carried out in the
PyroMark Q24 instrument (Qiagen). The degree of methyl-
ation of all five CpG sites was automatically analyzed by the
PyroMark Q24 software. A cutoff of 10% methylated DNA
content was defined as positive for p16 promoter hypermeth-
ylation. Primer sequences for CDKN2A first round PCR were
ATGGAGTTTTYGGTTGATTGGT (forward) and CCCCCC-
ATCCCCTACTCC (reverse). Primer sequences for CDKN2A
nested PCR were ATGGAGTTTTYGGTTGATTGGT (for-
ward), GGAGTTTTAGGTTGATTGGGTT (reverse), and
biot-CCCTCTACCCACCTAAAT (sequencing primer).
Statistical Analysis
The degree of agreement between observers was eval-
uated by interclass correlation coefficients, using reliability
Cronbach’s alpha analysis. Correlation analysis of clinico-
pathological and immunohistochemical parameters was per-
formed using the Spearman test; after correction for multiple
testing (0.05 divided by the number of analyzed parameters),
p values 0.008 were considered as significant. In addition,
for the three major histology types (ACA, SCC, and LCC),
the mean percentage of positively stained cells was com-
pared, and significant markers (p valueANOVA 0.005) were
further analyzed using the Kruskal-Wallis H test. The dis-
criminatory power of red to green FISH ratios to predict
immunohistochemical detectability of p16 was assessed by
means of ROC analysis, selecting expression of p16 as the
state variable. Optimal cutoff values were calculated using
the Youden index (J) for maximum of specificity and sensi-
tivity.22 The prognostic relevance of respective markers was
assessed also by means of ROC analysis, selecting death as
the state variable. Optimal cutoff values were calculated
using J for variables demonstrating an asymptomatic signif-
icance by ROC below 0.2 and an adequately shaped ROC
curve, otherwise the median was selected. Kaplan-Meier
curves were calculated for survival estimates and a log-rank
statistics used to determine differences between groups; mul-
tivariable analysis was performed using the Cox regression
model. p -values less than 0.05 were considered as signifi-
cant. Two-sided tests were used throughout. Statistical cal-
culations were performed using SPSS 19.0 software (SPSS,
Chicago, IL).
RESULTS
Histopathology and Patient Characteristics
Histological subtypes consisted of 193 ACAs, 123
SCCs, 54 LCCs, 8 adenosquamous carcinomas, 4 pleomor-
phic carcinomas, and 1 mucoepidermoid carcinoma. Twenty
were well differentiated, 161 moderately differentiated, and
202 poorly differentiated. Distribution of pathological tumor
stage by the Union Internationale Contre le Cancer (UICC)
was as follows: 103 stage IA, 113 stage IB, 19 stage IIA, 48
stage IIB, 63 stage IIIA, 18 stage IIIB, and 19 stage IV. The
patient population comprised 280 men and 103 women (ratio
2.7:1) with an average age of 63 years and a range from 23 to
84 years. For 193 of 383 (50.4%) patients, the smoking
history was known: 13 of 193 (6.7%) were never smokers,
145 of 193 (75.2%) were smokers (either current or quit less
than 2 years before diagnosis), and 35 of 193 (18.1%) were
former smokers (quit longer than 2 years before diagnosis).
Immunohistochemistry
Three hundred sixty-five cases qualified for evaluation
of immunohistochemistry. Eighteen cases were excluded due
to lack of tumor cells (20). By ROC analysis, p16 discrim-
ination power for overall survival time after radical surgery
resulted in: area under the ROC  0.537, 95% CI: 0.478–
0.598, and p  0.2. The calculated cutoff level (J) was 10%.
In all, 232 of 365 (63.6%) cases expressed p16 below the
cutoff level (loss of p16 expression), and 133 of 365 (36.4%)
cases were considered p16-positive. Cronbach’s alpha for
interobserver reproducibility of the immunohistochemistry
was excellent (  0.987). Most positive cases showed a
diffuse and strong staining pattern of all the tumor cells
(Figure 1A). Staining was localized to the cytoplasm in 84
cases, to the nucleus in two cases, and both nucleus and
cytoplasm were positively stained in 47 cases. Endothelial
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and mesenchymal cells served as a positive internal control
for negative tumors (Figure 1B). The mean percentage of
stained tumor cells for the entire cohort was 23.4% (range
0–100; median: 0). Mean percentage of stained tumor cells
according to main histological subtype was 12.8% for SCC,
29% for ACA, and 31.5% for LCC (p  0.001). Loss of p16
expression was frequently found in SCC (97/115, 84%) in
contrast to ACA (93/186, 50%). For distribution of cases
according to the main histological subtypes, see Table 1. The
cyclin D1 and epidermal growth factor receptor (EGFR)-
staining results have been described in detail earlier in the
text.21
Fluorescence In Situ Hybridization
Three hundred twenty-two cases were evaluable for
FISH. Problems related to the tissue preservation with weak
or lacking FISH signals were responsible for the majority of
noninformative cases (n  46), whereas problems related to
the TMA technology such as lacking punches accounted for
the minority of noninformative cases (n  15). The mean red
(9p21)/green (CEP9) ratio was 0.887, median 0.938, and
range 0.340–1.143. Altogether, 34 cases (10.4%) were con-
sidered to harbor 9p21 (p16) deletions with a mean red
(9p21)/green (CEP9) ratio of 0.502, median 0.515, and range
0.340–0.633 (Figure 1C). The nondeleted cases had a mean
red (9p21)/green (CEP9) ratio of 0.932, median 0.943, and
range 0.636–1.143 (p for difference between both groups
0.001). There were no NSCLC with homozygous p16
deletion. Because of slight nonoverlap of noninformative
cases for FISH and immunohistochemistry, in altogether 317
cases there was information on both deletion status and
protein expression (Figure 2).
p16 Pyrosequencing
To test the influence of 9p21 deletions and p16 pro-
moter hypermethylations on the p16 protein expression sta-
tus, we selected, based on best tissue preservation and taking
into account representation of the three major histological
subtypes (ACA, SCC, and LCC), nine nondeleted and p16-
negative cases, five nondeleted and p16-postive cases, nine
deleted and p16-negative cases, and five deleted and p16-
positive cases for methylation analysis by pyrosequencing.
Results are shown in Figure 2. Importantly, p16 promoter
hypermethylation was observable only in p16-negative cases
(6/18), whereas no hypermethylation was found among p16-
positive cases (0/9). p16 promoter hypermethylation was
twice as frequent in p16-deleted cases (4/9) compared with
nondeleted cases (2/9).
Correlations Between Variables
Loss of expression of p16 was associated with SCC
histology (Spearman correlation coefficient:   0.308; p 
0.001), earlier tumor stage (  0.162; p  0.002), and
increased expression of EGFR (  0.190; p  0.001) and
cyclin D1 ( 0.140, p 0.008). In contrast, p16 expression
was frequently detected in ACA (  0.286; p  0.001). A
lower ratio of 9p21/CEP9 (p16 gene deletion) correlated with
loss of p16 protein expression (: 0.173; p  0.002) and with
higher tumor grade (: 0.152; p 0.006). Case distribution of
p16 protein expression and gene status among major histo-
logical subtypes is shown in Table 2, and distribution of p16
protein expression and promoter hypermethylation among
major histological subtypes is shown in Table 3. Smoking
status did not correlate with p16 expression or gene status.
The combination of p16 gene deletion and promoter hyper-
methylation was not associated with other parameters, al-
though the small number of such cases (n 4) does not allow
precise conclusions.
Survival Analysis
The median follow-up time was 41.8 months, the lon-
gest being 181.1 months. Results for calculations of survival
estimates for the entire group are shown in Table 1. Loss of
p16 expression was associated with significantly worse over-
all survival for the whole cohort (Figure 3A). Within sub-
groups, this applied for patients aged 55 years or younger,
male gender (Figure 3B), smokers, pUICC stage IA and IB,
pN stage 0, pM stage 0, well or poor (not for moderate) tumor
differentiation, nonrecurring tumors, and for ACA (Figure
3C) and LCC histology. When patients were grouped as
either 65 years or younger or older than 65 years of age, loss
of p16 expression was also associated with significantly
worse overall survival for patients who were 65 years or
younger: 125 of 207 (60.4%) p16-negative patients had a
median overall postoperative survival time of 45.5 months,
compared with 84.5 months for 82 of 207 (39.6%) p16-
positive patients (p 0.002) (Figure 3D). Combined analysis
of p16 and cyclin D1 showed that cases with loss of p16 with
concurrent overexpression of cyclin D1 (cutoff  15% pos-
FIGURE 1. Immunohistochemistry for p16 demonstrating a
diffusely positive squamous cell carcinoma (A) and a nega-
tive adenocarcinoma with positively stained interspersed en-
dothelial and mesenchymal cells (B). Original magnification
40. (C) Fluorescence in situ hybridization analysis with a
locus-specific identifier (LSI) p16 (9p21) SpectrumOrange/
chromosome enumeration probe (CEP) 9 SpecturmGreen
dual-color mix. Note increased numbers (n  30) of green
(CEP9) compared with red (n  17) signals (9p21) (red/
green ratio 0.567) corresponding to p16 deletion.
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TABLE 1. Postoperative OS Analysis by Kaplan-Meier Estimates According to Clinicopathological
Parameters and p16 Expression
p16 Expression <10%,
No. of Patients (%)
Median OS in mo
Above (SD)
p16 Expression >10%,
No. of Patients (%)
Median OS in mo
Above (SD)
p
Median RFS in
mo Below (SD)
Median RFS in
mo Below (SD)
Parameter
All 232/365 (63.6) 40.8 (4.6) 133/365 (36.4) 67.2 (14.4) 0.002
51.8 (21.8) 115.3 (—) 0.101
Gender
Female 58/98 (59.2) 62.1 (28.8) 40/98 (40.8) 94.5 (25.4) 0.107
76.7 (32.6) NR 0.053
Male 174/267 (65.2) 35.7 (4.4) 93/267 (34.8) 52.8 (10.2) 0.012
46.0 (23.8) 75.6 (32.3) 0.507
Histology
ACA 93/186 (50) 38.9 (6) 93/186 (50) 72.5 (14.8) 0.020
42.0 (13.6) 93.2 (—) 0.117
SCC 97/115 (84.3) 51.5 (12) 18/115 (15.7) 49.8 (18.2) 0.463
NR NR 0.316
LCC 32/52 (61.5) 16.8 (8.9) 20/52 (38.5) 89.9 (39.2) 0.010
49.5 (23.7) 94.2 (55.0) 0.382
Other 10/12 (83.3) 18.9 (5.5) 2/12 (16.7) 59.7 (—) 0.395
8.0 (2.3) 28.4 (—) 0.402
Differentiation
Well 9/20 (45) 17.2 (36.1) 11/20 (55) 131.3 (46) 0.023
76.7 (22.5) NR 0.266
Moderate 98/155 (63.2) 54 (15.1) 57/155 (36.8) 61.2 (15.6) 0.219
65.7 (28.1) 86.5 (—) 0.802
Poor 125/190 (65.8) 36.3 (4.6) 65/190 (34.2) 49.8 (17.1) 0.029
42.0 (16.1) 115.3 (—) 0.153
Smoking status
Never smoker 6/11 (54.5) 47.5 (39.4) 5/11 (45.5) 76.2 (12.2) 0.643
76.7 (42.9) 73.9 (42.4) 0.852
Smoker 87/137 (63.5) 38.5 (7) 50/137 (36.5) 59.7 (13.7) 0.019
42.0 (12.3) 115.3 (—) 0.120
Former smoker 28/35 (80) 92.3 (18.7) 7/35 (20) 89.8 (25) 0.833
104.7 (51.9) NR 0.881
pUICC
IA 51/97 (52.6) 47.5 (7.9) 46/97 (47.4) 118 (20.5) 0.011
61.2 (—) NR 0.139
IB 79/110 (71.8) 61.6 (12) 31/110 (28.2) 121.2 (—) 0.009
120.6 (18.8) NR 0.848
IIA 12/19 (63.2) 33.1 (3.8) 7/19 (36.8) 75.1 (36.3) 0.210
26.6 (11.8) NR 0.062
IIB 35/43 (81.4) 40.8 (27.6) 8/43 (18.6) 39.9 (6.9) 0.237
46.0 (43.1) 14.8 (1.4) 0.239
IIIA 38/62 (61.3) 19.7 (6) 24/62 (38.7) 24 (13.5) 0.323
14.5 (5.5) 35.2 (59.6) 0.129
IIIB 9/17 (52.9) 13.8 (0.7) 8/17 (47.1) 22.9 (10.4) 0.767
NR 63.3 (39.7) 0.953
IV 8/17 (47.1) 15.1 (12.1) 9/17 (52.9) 25.2 (0.9) 0.360
27.8 (10.7) 18.2 (4.8) 0.729
(Continued)
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FIGURE 2. Flowchart of the assess-
ment of protein expression, gene
status and promoter hypermethyl-
ation of p16 in non-small cell lung
cancer.
TABLE 1. (Continued)
p16 Expression <10%,
No. of Patients (%)
Median OS in mo
Above (SD)
p16 Expression >10%,
No. of Patients (%)
Median OS in mo
Above (SD)
p
Median RFS in
mo Below (SD)
Median RFS in
mo Below (SD)
T stage
1 68/133 (51.1) 47.5 (6.5) 65/133 (48.9) 84.5 (18.7) 0.023
49.5 (14.3) NR 0.105
2 133/186 (71.5) 43.1 (9.9) 53 (28.5) 48.3 (13.4) 0.133
95.0 (27.8) 44.7 (28.3) 0.957
3 21/29 (72.4) 18.9 (6.8) 7/29 (827.6) 32.8 (—) 0.225
19.4 (9.4) NR 0.208
4 10/18 (55.5) 13.8 (7.4) 8/18 (44.5) 22.9 (10.4) 0.765
17.8 (10.6) 63.2 (39.7) 0.928
N stage
0 146/235 (62.1) 47.8 (7.5) 89/235 (37.9) 118 (20.3) 0.001
104.7 (27.1) NR 0.133
1 59/80 (73.7) 36.3 (7.4) 21/80 (26.3) 42.2 (6.8) 0.876
31.4 (19.8) 86.5 (59.5) 0.441
2 27/50 (54) 19.7 (6.2) 23/50 (46) 15.4 (5.7) 0.965
14.5 (4.9) 12.4 (3.1) 0.495
M stage
0 224/348 (64.4) 41.8 (5) 124/348 (35.6) 75.1 (11) 0.002
57.7 (23.6) 115.3 (—) 0.090
1 8/17 (47.1) 15.1 (12.1) 9/17 (52.9) 25.2 (0.9) 0.360
27.8 (10.7) 18.2 (7.8) 0.729
Recurrence
No 127/194 (65.5) 92.3 (14) 76/194 (34.5) 173.4 (43.9) 0.005
— — —
Yes 105/162 (64.8) 27.9 (3.1) 57/162 (35.2) 35.8 (4.8) 0.397
12.8 (2.0) 15.0 (2.1) 0.276
Age (yr)
55 43/78 (55.1) 31.2 (14.9) 35/78 (44.9) 173.4 (61.2) 0.006
19.2 (3.8) 115.3 (66.8) 0.077
55 to 65 82/129 (63.6) 62.1 (13.4) 47/129 (36.4) 84.1 (25.4) 0.082
57.7 (30.1) NR 0.099
65 to 75 79/116 (68.1) 31.6 (4.6) 37/116 (31.9) 52.8 (11.5) 0.212
76.7 (34.9) NR 0.672
75 28/42 (66.6) 40.7 (13.1) 14/42 (33.4) 42.2 (2.2) 0.910
NR 23.0 (42.1) 0.498
RFS, recurrence-free survival; SD, standard deviation; NR, not reached; OS, overall survival; ACA, adenocarcinoma; SCC, squamous
cell carcinoma; LCC, large-cell carcinoma; UICC, Union Internationale Contre le Cancer.
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itively stained tumor cells, as previously described) were
associated with the worst overall survival time, whereas cases
with detectable p16 expression and cyclin D1 levels below
the cutoff level demonstrated significantly longer survival
(p16/cylin D1: 106/363 [29.2%] cases, 76.2 months me-
dian; p16/cyclin D1: 27/363 [7.4%] cases, 42.2 months
median; p16/cyclin D1: 162/363 [44.6%] cases, 44.6
months median; and p16/cyclin D1: 68/363 [18.8%]
cases, 36.9 months median; p  0.03).21 p16 gene deletions
were associated with poor overall survival for women. Re-
currence-free survival (RFS) was defined as the time from
operation until disease recurrence, including patients without
recurrence who were censored at date of last follow-up or
death. Median RFS was 28.7 months. Results for calculations
of RFS are listed in Table 1. In this cohort, loss of p16
expression was not associated with significantly decreased
RFS time for the analyzed patient groups. The multivariable
analysis included all baseline (i.e., recurrence status ex-
cluded) parameters with a p value of less than 0.1 by uni-
variable analysis and revealed that only loss of p16 (relative
risk: 1.572, 95% CI: 1.026 – 2.410, p  0.038) was signifi-
cantly associated with decreased overall survival. Concerning
gene deletion of p16, the only significant result regarding
overall survival time in association with clinicopathologic
characteristics was shorter survival for female patients with
p16 deletions. In all, 70/79 (88.6%) women had no detectable
p16 gene deletion and a median overall survival period of
83.8 months, compared with 9 of 79 (11.4%) with deletions
and a median overall survival of 32.7 months (p  0.003).
FIGURE 3. Kaplan-Meier estimates
of overall survival according to ex-
pression of p16 for the entire cohort
(A), for men (B), for adenocarcino-
mas (C), and for patients aged 65
years or younger (D).
TABLE 2. Case Distribution of p16 Protein Expression and
Gene Status Among Major Histological Subtypes
SCC (%) ACA (%) LCC (%)
p16 expression 10% and
gene deletion
10 (9.7) 6 (3.9) 1 (2)
p16 expression 10% and
no gene deletion
9 (8.7) 73 (47.8) 13 (26)
p16 expression 10% and
gene deletion
5 (4.9) 6 (3.9) 5 (10)
p16 expression 10% and
no gene deletion
79 (76.7) 68 (44.4) 31 (62)
Total 103 153 50
SCC, squamous cell carcinoma; ACA, adenocarcinoma; LCC, large-cell carcinoma.
TABLE 3. Case Distribution of p16 Protein Expression and
Promoter Methylation Among Major Histological Subtypes
SCC (%) ACA (%) LCC (%)
p16 expression 10% and
hypermethylation
4 (36.4) 2 (18.1) 0
p16 expression 10% and
no hypermethylation
2 (18.1) 5 (45.5) 3 (60)
p16 expression 10% and
hypermethylation
0 0 0
p16 expression 10% and
no hypermethylation
5 (45.5) 4 (36.4) 2 (40)
Total 11 11 5
SCC, squamous cell carcinoma; ACA, adenocarcinoma; LCC, large-cell carcinoma.
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DISCUSSION
This population-based study underlines and extends the
importance of p16 for surgically resected NSCLC. We found
that loss of p16 protein expression is frequent in NSCLC and
is an especially common feature of SCC compared with
ACA, which is well in line with most smaller previous
studies.11,23 Loss of p16 expression was more frequently
observed in earlier tumor stages, although because this is a
study of surgically resected NSCLC, there is a natural bias
considering tumor stage with proportionally fewer advanced
tumors. Expression of p16 and cyclin D1 showed an inverse
correlation, which has also been reported by Myong23 and
reflects their functions in the cell cycle. Because p16 inhibits
cdks, which become active when bound to cyclin D1, loss of
p16 protein can lead to elevated levels of cyclin D1 protein.
In our cohort, cases positive for EGFR as assessed by immu-
nohistochemistry more commonly showed loss of p16 ex-
pression. This further emphasizes the importance of deregu-
lation of the cell cycle in NSCLC, because activation of
EGFR leads to stimulation of the cell cycle whereas p16 is a
negative regulator. Such inverse correlations are likely to
both stimulate the cell cycle and diminish its inhibition at the
same time. Jin et al.12 stressed that the combination of cyclin
D1 expression with loss of p16 expression is very useful to
predict the prognosis of patients with NSCLC after curative
resection. Indeed, in our collective, the combination of p16
expression loss with cyclin D1 overexpression was associated
with reduced overall survival time compared with p16-ex-
pression-negative cases with low levels of cyclin D1 expres-
sion. For the entire cohort, loss of p16 expression was
associated with poor survival, which has previously been
widely reported.13,23 Subgroup analysis revealed that this was
only the case for younger patients, male gender, smokers,
early tumor stages (pUICC IA and IB), well or poor (not for
moderate) tumor differentiation, nonrecurring disease, and
for ACA and LCC histology. Few studies have commented
on survival with regard to histology, resulting in no associa-
tion and in divergent findings.14,24 Notably, to the best of our
knowledge, no studies have linked poor survival and loss of
p16 expression to age, whereas our data show significantly
shorter overall survival time for patients who are 65 years or
younger. p16 expression proved to be an independent prog-
nostic factor by multivariable analysis, in line with other
reports analyzing surgically resected NSCLC by immunohis-
tochemistry.13,15 Loss of p16 protein expression by immuno-
histochemistry is known to be an accurate method for detec-
tion of p16 gene inactivation events.25 Distinct mechanisms
include gene deletions and promoter hypermethylation,
whereas point mutations are rare.25 Although such mecha-
nisms have been described in lung cancer, they have not been
assessed simultaneously in a single large tumor series with
incorporation of p16 protein expression. Especially the tim-
ing of such occurrences is unclear. As expected, a decreased
ratio of 9p21/CEP9 correlated with loss of p16 protein ex-
pression and was also more common in higher tumor grades.
Our data demonstrate that p16 gene deletions occur at a
similar frequency in NSCLC whether p16 protein expression
was below or above the cutoff level of 10% (deletion fre-
quency: 8.3% for cases below and 14.2% for cases above the
cutoff level). This implies that loss of protein expression is
not solely caused by a gene deletion. A likely explanation for
the expression of p16 protein despite p16 deletion is
heterozygous deletion. Homozygous deletions on the other
hand should be sufficient for loss of protein. In our collective,
the 9p21/CEP9 ratio was assessed by FISH, and a cutoff
value of 0.636 was established for determining cases harbor-
ing a deletion. No tumor had a ratio less than 0.340, thus
virtually excluding the possibility of a biallelic deletion. This
is in contrast to the study by Gazzeri et al.,25 who reported
frequent homozygote deletions, although they analyzed touch
preparations, which is not comparable to our method of
interphase FISH on TMA slides.
Given that most SCC were p16-negative, the SCC
group of p16-positive cases with nondeleted p16 gene is
especially interesting. Because there may be a connection
with human papillomavirus (HPV) infection (e.g., as known
for cervical cancer) in SCC expressing p16, we analyzed this
group separately regarding a possible viral association. Inter-
estingly, viral infection has also been reported to correlate
with better differentiation in SCC of the lung.26 This small
group consisted of nine cases (8.7% of all SCC). Notably,
eight patients were men, and the median overall survival time
was 73 months compared with 44.7 months for the entire
SCC cohort. Tumor stage and grade, Ki67 index, and smok-
ing status did not differ considerably (results not shown). In
addition, we performed immunohistochemistry using the Cy-
toactiv HPV L1 Screening Set (detection of HPV L1 capsid
protein) and the Cytoactiv HPV L1 High Risk Set (detection
of L1 capsid protein of the high risk HPV subtypes: 16, 18,
31, 33, 35, 39, 45, 56, and 58) (both from Cytoimmun
Diagnostics GmbH, Pirmasens/Germany). No case showed a
positive nuclear staining signal, thus as expected prognosis
was indeed better, although no indication of HPV infection
was apparent.
Our cases for gene promoter methylation analysis were
selected on grounds to best represent the different groups
regarding p16 expression and p16 gene status (Figure 2).
From the analyzed group of tumors with loss of p16 expres-
sion, nine p16 deleted and nine p16 nondeleted cases were
selected. Considering cases with p16 expression, four evalu-
able of five analyzed cases had deleted and five had nonde-
leted genes. None of the cases with p16 expression 10%
showed hypermethylated promoter regions (independent of
deletion status). However, tumors with loss of p16 expression
more commonly harbored p16 promoter hypermethylation as
well, which was twice as frequent for cases with p16 gene
deletions (4/9) compared with p16 nondeleted instances (2/9).
This suggests that hypermethylation of the promoter region of
p16 is most likely the initial step toward loss of p16 function
in NSCLC, followed by heterozygous deletion, which finally
results in complete loss of protein expression. Studies have
demonstrated that aberrant p16 promoter hypermethylation is
an early and critical event in the development of NSCLC,
supporting our assumption.27 Such p16 promoter hypermeth-
ylation has even been observed in serum and sputum of
chronic smokers without clinical disease.8 Analogously to the
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more frequently observed losses of p16 expression in SCC,
p16 promoter hypermethylations have also been more fre-
quently detected in SCC compared with ACA.7 For cases
with loss of p16 expression and no detectable deletion or
hypermethylation, the possibility of mutations, and yet unde-
termined mechanisms of genetic or epigenetic inactivations
must be considered.
The importance of the mechanism of gene promoter
hypermethylation lies in the possibility of epigenetic treat-
ment options. 5-Azacytidine is a demethylating agent, which
inhibits DNA methyltransferase-1 in replicating cells, and
5-aza-deoxycytidine triphosphate (decitabine) is a resulting
5-azacytidine by-product with an additional cytotoxic effect
through its incorporation into RNA.28 Recently, azacytidine
has been shown to prolong survival and improve quality of
life in patients with myelodysplastic syndromes, while main-
taining a favorable adverse effect profile.9 A recent interim
analysis of a phase II trial has reported that the combination
of azacytidine and entinostat (inhibitor of histone deacety-
lase) has a durable benefit in patients with advanced relapsed
NSCLC.10 Pharmacodynamic and pharmacokinetic analyses
are being conducted to identify characteristics of the subset of
patients responding to this novel therapy.
In conclusion, our data would be compatible with a
two-step process leading to loss of p16 protein expression in
NSCLC. Hypermethylation of the promoter region of p16
may present the first event, followed by heterozygote deletion
of the p16 gene locus. We also confirm that loss of p16
expression is a frequent event in NSCLC and is associated
with poor survival especially for certain patient subgroups.
Considering the possibility of detection of hypermethylated
gene regions, these data may lead to the identification of
patient subgroups more likely to benefit from upcoming
epigenetic treatment strategies.
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